A team from The Scripps Research Institute (TSRI) has developed a new strategy to curb addiction and even prevent fatal overdoses of synthetic opioid designer drugs. In a new study (“Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs”), published in Angewandte Chemie, the scientists report successful preclinical tests of a vaccine that prevents fentanyl, which some drug dealers now use as a mix-in or substitute for heroin, from reaching the brain.
“We want to stay one step ahead of these clandestine laboratories making illegal opioids for black market demand,” said Kim Janda, Ph.D., the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. “The importance of this new vaccine is that it can block the toxic effects of this drug, a first in the field.”
Fentanyl is a painkiller 50 to 500 times more potent than morphine. With so many variants on the market, users have no way of knowing the strength of the drugs they are using, which can lead to fatal overdoses. The U.S. Centers for Disease Control and Prevention reported a 200% increase in overdose deaths involving opioids from 2000 to 2014, citing the availability of fentanyl and fentanyl variants as a major contributor.
While there are treatments such as naloxone for opioid overdose or methadone for addiction, Dr. Janda noted that many people still relapse. “These treatments are working for some people, but there is clearly a gap that needs attention,” he said.
The new vaccine takes advantage of the body's own immune system. The vaccine cocktail contains a molecule that mimics fentanyl's core structure. When given the vaccine, the immune system is “trained” to produce antibodies to neutralize it. The idea is that when a person then tries to get high from fentanyl or its variants, their antibodies bind to the drug and keep it from reaching the brain. In theory, blocking the ability to feel a high could stop drug-seeking and drug-taking behavior.
Dr. Janda and his colleagues tested the vaccine in mouse models of fentanyl addiction and overdose. Mice were given three vaccinations, each two weeks apart, like a series of booster shots. By studying antibodies in the blood, the researchers saw that the immune system was successfully neutralizing fentanyl for months after the last injection. In further tests, the researchers observed that vaccinated mice given fentanyl did not demonstrate “high” behavior (such as ignoring discomfort).
In fact, a 30-fold greater-than-normal dose of fentanyl was necessary for the drug to activate neural circuits in vaccinated mice. Antibodies generated by the vaccine protected against overdose, neutralizing lethal levels of fentanyl.
“To the best of our knowledge, our active vaccine is the first to ablate lethal doses of any drug of abuse,” said TSRI Research Associate Atsushi Kimishima, co-first author of the new study with TSRI graduate student Paul Bremer.
Importantly, the potential vaccine protects against virtually all fentanyl derivatives and does not cross-react with other drug classes, such as oxycodone. This means those vaccinated would still have painkiller options in medical situations.
The researchers said the next step in this research is to design an even more potent vaccine, perhaps a combined anti-fentanyl and heroin vaccine. “Since heroin is often cut with fentanyl derivatives, a combination vaccine targeting both opioids would be worth investigating,” said Bremer.